» Articles » PMID: 9643476

In Vitro Effects of Smokeless Tobacco Extract on Tumor Necrosis Factor-alpha (TNF-alpha) and Interleukin-1beta (IL-1beta) Production, and on Lymphocyte Proliferation

Overview
Journal Toxicon
Specialty Toxicology
Date 1998 Jun 27
PMID 9643476
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The use of smokeless tobacco (moist snuff) products is associated with mucosal lesions, gingival recession, attachment loss, and oral cancer. Despite numerous reports on the general toxic effects of smokeless tobacco extract, little information is available regarding the specific effects of smokeless tobacco on immune response. Inflammatory cytokines released as a result of smokeless tobacco-induced irritation may play a role in the development of oral mucosal lesions at habitual tobacco placement sites in smokeless tobacco users. Consequently, the purpose of this study was to determine whether an aqueous extract of smokeless tobacco (STE) affects the secretion of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and the proliferation of lymphocytes. A macrophage cell line (J774-A1) was used to measure the effects of STE on tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) secretion. Mouse splenocytes were used to assess the effects of STE on lymphocyte proliferation. We found that STE at low concentrations enhanced the production of both TNF-alpha and IL-1beta. Furthermore, STE at similar concentrations enhanced mitogen-induced murine splenocyte proliferation. Overall, these data suggest that smokeless tobacco upregulated two key proinflammatory cytokines and also induces lymphocyte proliferation.

Citing Articles

Comparison of severity of periodontal clinical parameters among naswar/snuff users: Cross sectional study.

Rahim A, Syed K, Ahad B, Farooq A, Ayub Z, Batool S PLoS One. 2022; 17(9):e0273288.

PMID: 36112584 PMC: 9481047. DOI: 10.1371/journal.pone.0273288.


The effect of a non-tobacco-based nicotine pouch on mucosal lesions caused by Swedish smokeless tobacco (snus).

Alizadehgharib S, Lehrkinder A, Alshabeeb A, Ostberg A, Lingstrom P Eur J Oral Sci. 2022; 130(4):e12885.

PMID: 35853092 PMC: 9540014. DOI: 10.1111/eos.12885.


Looking beyond the smokescreen: can the oral microbiome be a tool or target in the management of tobacco-associated oral cancer?.

Kadam S, Vandana M, Patwardhan S, Kaushik K Ecancermedicalscience. 2021; 15:1179.

PMID: 33777172 PMC: 7987485. DOI: 10.3332/ecancer.2021.1179.


Evaluation of systemic inflammatory and thrombotic markers of cardiovascular risk among young Indian oral tobacco users.

Zutshi D, Gupta M, Girish M, Bansal A, Batra V, Saijpaul R Indian Heart J. 2020; 72(5):389-393.

PMID: 33189199 PMC: 7670266. DOI: 10.1016/j.ihj.2020.08.005.


Association of -330 interleukin-2 gene polymorphism with oral cancer.

Singh P, Kumar V, Ahmad M, Gupta R, Mahdi A, Jain A Indian J Med Res. 2018; 146(6):730-737.

PMID: 29664031 PMC: 5926344. DOI: 10.4103/ijmr.IJMR_1949_15.